Experimental cell therapy aims to prevent relapse in aggressive childhood cancers

This early-phase study is testing whether a personalized cell therapy called CD7 CAR-T can help prevent cancer from returning in children and teenagers with high-risk T-cell leukemia or lymphoma. Participants must have already achieved remission with initial chemotherapy but remain at high risk of relapse. Doctors will collect the patients' own immune cells, modify them in a lab to target cancer, and reinfuse them to see if this approach is safe and effective at keeping the cancer away.